Roche’s vamikibart sustains vision gains for 52 weeks as July 2027 FDA decision approaches

Genentech, a subsidiary of Swiss pharmaceutical group Roche Holding AG (SIX: ROP, RO; OTCQX: RHHBY), has reported new 52-week Phase III findings for investigational vamikibart, an interleukin-6-targeting antibody being developed for uveitic macular edema, a potentially sight-threatening complication of ocular inflammation. Presented at the American Academy of Ophthalmology 2026 annual meeting in New Orleans on October 10, the results from the MEERKAT and SANDCAT studies showed sustained improvements in visual acuity and reductions in macular thickness, with approximately two-thirds of eligible patients requiring no additional treatment after the initial 16-week period. The US Food and Drug Administration (FDA) has accepted Genentech’s Biologics License Application, with an approval decision expected by July 2027, while regulatory submissions have also been accepted for review in the European Union, China and Japan. The development could provide Roche with a targeted, locally administered, non-steroid option in an area where corticosteroids remain widely used despite their recognised ocular risks. However, the regulatory assessment must account for a significant difference between the pivotal trials: MEERKAT achieved statistically significant superiority on its original primary endpoint, while SANDCAT did not, making the interpretation of the combined efficacy and safety evidence central to the drug’s future.

What do Genentech’s new 52-week vamikibart results show about sustained vision improvement?

The latest findings extend the clinical assessment of vamikibart beyond the initial 16-week primary analysis presented in October 2025. Genentech reported that visual acuity improvements and reductions in retinal swelling were maintained through 52 weeks across both Phase III studies. These findings suggest that the treatment’s initial effects may persist over a longer period, an important consideration for a condition in which recurrent inflammation and fluid accumulation can threaten vision. However, the October 2026 announcement did not provide a complete numerical breakdown of visual acuity changes, retinal thickness measurements or statistical comparisons at week 52.

The company described a numerically higher proportion of vamikibart-treated patients achieving substantial visual improvement than patients in the sham comparator groups at one year. It also reported sustained improvements in mean best corrected visual acuity, or BCVA, and central subfield thickness, a measurement used to assess swelling in the macula. These measures evaluate related but distinct aspects of treatment effectiveness. BCVA assesses functional vision, while retinal thickness provides anatomical evidence of whether the underlying edema has improved.

The distinction is relevant because reducing retinal swelling does not always translate into an equivalent improvement in visual function. Patients with longstanding inflammation may experience structural retinal damage that limits the degree of vision recovery even when fluid accumulation is reduced. A treatment capable of improving both measures could offer a more clinically meaningful benefit than one affecting retinal anatomy alone. The new findings support Genentech’s assessment of sustained activity, although detailed numerical data and the earlier differences between studies remain necessary for evaluating the strength of the evidence.

The results also provide information about the treatment’s durability after the initial dosing period. Genentech reported that approximately two-thirds of eligible patients did not require retreatment after week 16, while most patients who required further treatment received only one additional injection. This suggests that selected patients may maintain disease control without continuous monthly injections throughout the entire first year. The reported figure does not mean that two-thirds of all enrolled participants received only one injection, because the initial treatment period involved repeated dosing.

Why did MEERKAT meet its primary endpoint while SANDCAT failed to demonstrate the same statistical result?

The most important qualification to the new durability findings is the difference between the original pivotal trial outcomes. MEERKAT and SANDCAT were designed as parallel, randomised, double-masked, sham-controlled Phase III studies evaluating two doses of vamikibart in patients with uveitic macular edema. The primary endpoint in both trials was the proportion of patients achieving an improvement of at least 15 letters in best corrected visual acuity at week 16. This threshold represents approximately three lines on a standard clinical vision chart and is commonly used to assess substantial visual improvement in ophthalmology trials.

MEERKAT enrolled 245 participants and demonstrated statistically significant superiority for both tested doses on the primary endpoint. Patients receiving the 1 mg dose showed a 36.9 percentage-point higher response rate than the sham comparator group, with a reported P value below 0.0001. The 0.25 mg dose produced a 19.9 percentage-point difference compared with sham, with a P value of 0.0008. These results provided substantial evidence of treatment activity in the first pivotal study.

SANDCAT enrolled 256 participants but did not reproduce the same confirmatory statistical result. The 1 mg dose produced a 10.9 percentage-point difference over sham on the primary endpoint, with a P value of 0.0699, which did not reach the conventional 0.05 threshold. The 0.25 mg dose showed a 20.7 percentage-point difference and a nominally significant result, but it did not meet the study’s formal statistical success criteria. Consequently, it would be inaccurate to describe both pivotal studies as having achieved their original primary endpoints.

The results nevertheless showed evidence of activity across other measures. In MEERKAT, the 1 mg dose produced an average improvement of 12.8 BCVA letters at week 16, compared with 3.5 letters in the sham group. In SANDCAT, the corresponding improvements were 9.2 letters and 5.0 letters. These findings support the broader efficacy assessment, but differences between treatment groups on secondary outcomes must be interpreted within each study’s statistical testing framework.

Genentech previously identified variability in visual acuity measurements, differences in baseline characteristics and concomitant medication use as possible contributors to the divergence between trials. Those explanations are plausible areas for investigation but should not be treated as established reasons for SANDCAT’s failure to meet its primary endpoint. The FDA will need to evaluate whether the combined evidence supports a favourable conclusion for the proposed indication. The 52-week follow-up strengthens the available evidence on persistence of response without retroactively converting SANDCAT’s original primary analysis into a statistically successful result.

How does vamikibart’s interleukin-6 mechanism differ from conventional steroid treatment for uveitic macular edema?

Vamikibart is an investigational monoclonal antibody designed for injection into the eye and engineered to inhibit interleukin-6, an inflammatory signalling protein involved in several immune pathways. In uveitic macular edema, ocular inflammation can disrupt normal retinal fluid regulation, contributing to swelling of the macula and deterioration in central vision. Targeting IL-6 offers an approach intended to interfere with a specific inflammatory pathway associated with the condition. This differs from corticosteroids, which act more broadly across multiple inflammatory processes.

Uveitic macular edema is a major cause of visual impairment among patients with uveitis, particularly because inflammation can recur or persist over time. The condition frequently affects working-age adults, potentially interfering with employment, driving, reading and other activities requiring clear central vision. Genentech has cited research indicating that approximately 20% of patients with UME may progress to sustained blindness within three years of diagnosis. Such estimates depend on the populations studied and should not be interpreted as the expected outcome for every treated patient.

Corticosteroids remain widely used in managing ocular inflammation and associated macular edema. Depending on the clinical situation, treatment may involve systemic medication, local injections or sustained-release ocular implants. Although these approaches can control inflammation, prolonged or repeated corticosteroid exposure can increase intraocular pressure and contribute to glaucoma or cataract development. Those complications create a rationale for treatments that can control ocular inflammation through alternative mechanisms.

Vamikibart’s potential advantage is that it targets IL-6 without using a corticosteroid mechanism. However, the MEERKAT and SANDCAT studies compared the investigational therapy with sham procedures rather than directly comparing it with a recognised steroid treatment. The trials therefore do not establish that vamikibart is more effective than corticosteroids, reduces cataract development or prevents glaucoma. Its value relative to current practice will depend on the final approved indication, safety findings and clinical experience after any commercial introduction.

The targeted mechanism could nevertheless appeal to clinicians treating patients who face limitations with existing therapies. Some individuals may have a history of elevated intraocular pressure or glaucoma, conditions that can complicate decisions involving repeated ocular steroid exposure. The Phase III programme included participants with histories of raised intraocular pressure and glaucoma, providing relevant clinical experience in such patients. However, eligibility in a trial does not establish that the investigational medicine eliminates ocular pressure risks or is suitable for every patient in those groups.

Can the reported low retreatment burden support a more attractive treatment profile?

Treatment frequency can influence the practical value of an ophthalmic medicine because intravitreal injections require specialist administration and repeated clinical appointments. Patients may need to arrange travel, time away from work and follow-up monitoring, while healthcare providers must allocate injection and examination capacity. A therapy that maintains benefit with fewer additional injections could therefore offer operational and patient convenience advantages, provided that clinical outcomes remain satisfactory. The latest results offer preliminary support for that possibility.

In both pivotal studies, participants were initially assigned to receive 0.25 mg vamikibart, 1 mg vamikibart or sham procedures at four-week intervals during the first 16 weeks. Thereafter, treatment was administered as needed through week 52 according to the study protocol. Genentech’s statement that approximately two-thirds of eligible patients required no retreatment after week 16 therefore applies to the maintenance period rather than the entire treatment course. The company has not disclosed sufficient detail in the October announcement to establish a complete year-one injection distribution for every dose group.

The eligibility qualification also requires consideration. A retreatment percentage calculated among eligible participants is not necessarily equivalent to the proportion of all randomised patients who maintained disease control without further intervention. The interpretation may depend on assessment criteria, follow-up completion and the clinical rules governing additional treatment. More detailed results would help establish the relationship between retreatment decisions, visual acuity outcomes and changes in retinal thickness.

The clinical benefit of reduced treatment burden must also be assessed against the need for continuing monitoring. Patients whose edema improves may still experience recurrent inflammation or changes in their underlying uveitis that require treatment. Longer injection intervals therefore do not eliminate the need for appropriate follow-up or establish permanent disease remission. Future treatment guidance would need to clarify the approved dosing schedule and conditions under which retreatment is recommended.

What do the Phase III safety findings establish about ocular inflammation and injection-related risks?

Genentech reported that vamikibart remained generally well tolerated through the 52-week follow-up, with a low incidence of treatment-related ocular adverse events and intraocular inflammation. These findings are relevant because the drug is administered directly into the eye and targets an inflammatory pathway. Intravitreal medicines require careful evaluation of local tolerability, inflammatory reactions and other ocular safety outcomes. However, the October release did not provide complete one-year adverse-event rates by dose and comparator group.

The earlier 16-week safety findings offer additional context. In MEERKAT, treatment-related ocular adverse events were reported in 4.1% of patients receiving 0.25 mg and 1.3% of those receiving 1 mg. The corresponding figures in SANDCAT were 4.7% and 3.5%, compared with 3.7% in the SANDCAT sham group. The studies also reported relatively low rates of intraocular inflammation, with no retinal occlusive vasculitis events identified in the original 16-week analysis.

The most common adverse events reported among vamikibart-treated patients during the earlier analysis included conjunctival haemorrhage and increased intraocular pressure. These events are important when evaluating whether a new non-steroid therapy offers advantages over existing treatment approaches. A medicine may avoid the pharmacological effects of corticosteroids while still carrying risks related to injection procedures, local inflammation or other mechanisms. The absence of a particular serious event in a limited trial population also cannot establish that its risk is zero.

The 52-week safety evidence increases the duration of observation but does not eliminate uncertainty surrounding uncommon adverse reactions. Larger treated populations and longer periods of clinical use may identify events that do not occur frequently enough to be detected in pivotal trials. The FDA will evaluate the available safety information alongside efficacy, manufacturing quality and the proposed treatment regimen. Any eventual product labelling could include warnings, monitoring recommendations or other requirements that influence clinical adoption.

Why is the July 2027 FDA decision a significant regulatory milestone for Roche and Genentech?

The FDA has accepted Genentech’s Biologics License Application for vamikibart in uveitic macular edema, with a decision expected by July 2027. Acceptance means the agency has determined that the application is sufficiently complete to proceed through substantive review. It does not mean the FDA has concluded that the medicine is safe and effective or that marketing authorisation has been granted. The agency may request further information, examine clinical and manufacturing data, or take other regulatory actions before completing its review.

The submission is supported by the MEERKAT and SANDCAT pivotal programmes, including the original efficacy analyses and subsequent follow-up information. The central regulatory issue will be whether the totality of evidence provides an adequate basis for approval despite the difference between the trials’ primary endpoint results. Consistency across visual acuity and anatomical outcomes may contribute to the benefit-risk assessment, but the exact regulatory interpretation cannot be established from the company’s announcement. The 52-week durability findings may provide valuable supporting information rather than functioning as a replacement for the original primary endpoint analyses.

Regulatory submissions have also been accepted for review in the European Union, China and Japan. These developments broaden the geographic scope of the potential commercial opportunity, although each authority follows its own regulatory framework and may reach an independent decision. Acceptance for review should not be confused with marketing approval, and the company has not provided confirmed approval dates for all jurisdictions. Product availability would also depend on any country-specific conditions, reimbursement arrangements and commercial launch preparations.

Vamikibart has orphan drug designation in the United States and European Union. That status recognises its development for a rare condition under the applicable regulatory criteria and may provide certain development incentives and potential commercial benefits. However, orphan designation does not establish clinical efficacy, guarantee approval or automatically confer market exclusivity without the relevant approval and statutory conditions. The designation is therefore relevant to development strategy but should not be treated as a substitute for the FDA’s assessment of the Phase III evidence.

If approved for the proposed indication, Genentech believes vamikibart could become the first specifically targeted, non-steroid treatment for uveitic macular edema. That position may create opportunities among clinicians seeking alternatives to existing corticosteroid-based approaches. Nevertheless, prescribing patterns will depend on the approved indication, treatment schedule, safety profile, reimbursement and how the therapy performs in clinical practice. Regulatory authorisation would mark the beginning of commercial adoption rather than guaranteeing a new standard of care.

How would an approved vamikibart strengthen Roche’s existing ophthalmology business?

Roche has an established international ophthalmology business through products such as Vabysmo, which is approved for several retinal vascular conditions. The addition of vamikibart could expand its therapeutic presence into inflammatory retinal disease, potentially broadening relationships with ophthalmologists treating complex causes of vision loss. The prospective product would address a different mechanism and patient population from Roche’s existing major retinal therapies. This diversification could be strategically valuable, although it would not automatically translate into material group-level revenue.

The company’s financial scale provides context for the opportunity. Roche reported CHF30.4 billion in consolidated sales during the first half of 2026, with its Pharmaceuticals Division contributing approximately CHF23.6 billion. Pharmaceutical revenue increased 6% at constant exchange rates, although reported Swiss franc revenue declined slightly because of currency movements. Core operating profit increased 10% at constant exchange rates to approximately CHF11.9 billion, demonstrating continued growth across the wider business.

Vabysmo generated CHF2.06 billion in sales during the first six months of 2026, an increase of approximately 8% at constant exchange rates. That performance illustrates Roche’s established commercial infrastructure in retinal medicine, including specialist relationships and experience supporting injectable ophthalmic therapies. Such capabilities could help the company prepare for a vamikibart launch if approval is obtained. However, Vabysmo serves larger and different disease categories, making its sales an inappropriate proxy for vamikibart’s potential revenue.

The addressable market for uveitic macular edema is difficult to quantify from the currently disclosed information. The condition is relatively uncommon compared with major retinal diseases such as neovascular age-related macular degeneration or diabetic macular edema. Its potential commercial market depends on diagnosed patient numbers, treatment eligibility, competing therapies, pricing and the proportion of patients requiring repeated treatment. Genentech has not provided a specific annual sales forecast or independently validated addressable market estimate for vamikibart.

The commercial model may also be influenced by the treatment’s apparent durability. If a substantial proportion of patients can maintain benefit without frequent additional injections, the medicine may offer practical advantages to patients and healthcare systems. At the same time, fewer injections per patient could affect recurring treatment volume, depending on pricing and treatment patterns. The eventual revenue opportunity will therefore require an assessment of patient access, dosing frequency and reimbursement rather than extrapolating directly from the clinical durability findings.

How did Roche shares trade before the new Phase III results were released?

Roche’s non-voting participation certificates closed at CHF357.80 on the SIX Swiss Exchange on October 9, 2026, rising 1.45% from the previous session’s CHF352.70 close. The certificates gained approximately 2.6% over the five trading sessions from October 5 to October 9. The corresponding US-traded American depositary receipts, under the symbol RHHBY, closed at $54.09 on October 9, advancing 1.35% during that session. These movements occurred before the October 10 vamikibart announcement.

The timing prevents the October 9 price gains from being described as a direct market reaction to the newly presented one-year results. Roche’s shares are influenced by a substantially broader portfolio of pharmaceutical and diagnostics products, research programmes and financial developments. Even a promising clinical milestone in ophthalmology may have a limited immediate impact on the valuation of a company of Roche’s scale when the treatment’s potential revenue remains unquantified. Subsequent trading and analyst commentary would be needed to assess any identifiable market response.

Roche’s next scheduled financial update is its third-quarter 2026 sales presentation on October 22. That report will provide a more recent assessment of the group’s commercial performance and product portfolio trends. However, the company has not indicated that it will disclose additional vamikibart clinical findings or a dedicated sales forecast during that presentation. The more directly relevant regulatory milestone remains the FDA decision expected by July 2027.

For shareholders, the financial significance of vamikibart will ultimately depend on whether regulatory approval is obtained and whether the treatment achieves meaningful clinical adoption. The opportunity to enter a specialised inflammatory retinal disease category could complement Roche’s established ophthalmology activities. However, the therapy’s potential revenue contribution is unlikely to be reliably estimated without clearer information about eligible patient populations, pricing and treatment frequency. A clinical development milestone should therefore remain distinct from a quantified earnings forecast.

What evidence will determine whether vamikibart becomes an important treatment for uveitic macular edema?

The most immediate evidence will come from the regulatory assessment of the combined Phase III results. The original MEERKAT and SANDCAT outcomes create an unusual evidence profile because the studies showed directionally supportive findings but did not both achieve formal statistical success on their primary endpoints. The one-year data strengthen the understanding of durability and tolerability, but the regulatory significance will depend on the complete clinical dataset and the FDA’s evaluation. Approval would establish that the agency considers the benefit-risk profile favourable for the authorised use, subject to any specific conditions.

More detailed publication of the 52-week results would improve the independent assessment of treatment performance. Particularly useful information would include response rates by treatment group, statistical comparisons, changes in vision and retinal thickness, and the full distribution of retreatment requirements. Longer follow-up on ocular adverse events would also help clinicians evaluate the product’s potential position relative to established treatment approaches. These details would clarify how broadly the reported durability findings apply across patients with different disease characteristics.

Commercial adoption will introduce further questions. A targeted non-steroid treatment may offer a valuable option for patients who face difficulties with conventional therapies, but the availability of a new medicine does not establish superiority across every clinical scenario. Ophthalmologists will need to evaluate its effectiveness alongside existing corticosteroids, immunomodulatory approaches and other treatments selected according to the underlying cause of uveitis. Reimbursement decisions and specialist access will also influence how widely the medicine can be used.

The latest announcement advances vamikibart’s clinical development by showing that initial visual and anatomical improvements can be maintained through one year in the studied populations. Its treatment-burden findings provide a potential differentiating feature, while regulatory filing acceptance moves the programme into a more consequential stage. Nevertheless, the differences between the original pivotal results and the absence of direct comparative evidence against steroids remain important limits on interpretation. The decisive next step will be the FDA’s benefit-risk determination, followed by evidence that any approved treatment can deliver reliable outcomes and practical advantages in routine clinical care.

Key takeaways from Roche’s vamikibart Phase III results and July 2027 FDA decision

• Genentech reported 52-week results from the Phase III MEERKAT and SANDCAT studies evaluating vamikibart for uveitic macular edema.
• Both studies showed sustained improvements in visual acuity and reductions in macular swelling according to the company’s latest analysis.
• Approximately two-thirds of eligible participants required no retreatment after the initial 16-week dosing period.
• MEERKAT achieved statistically significant superiority on its original 16-week primary endpoint, while SANDCAT did not.
• Vamikibart targets interleukin-6 and is designed as a locally administered, non-steroid treatment for inflammation-related retinal edema.
• The latest safety update reported low rates of treatment-related ocular adverse events and intraocular inflammation, without providing complete one-year event rates.
• The FDA has accepted the Biologics License Application and is expected to issue a decision by July 2027.
• Regulatory applications have also been accepted for review in the European Union, China and Japan, with approvals not yet granted.
• Roche’s existing ophthalmology business includes Vabysmo, which generated CHF2.06 billion in first-half 2026 sales, but vamikibart’s revenue potential remains undisclosed.
• The regulatory decision, detailed durability data, safety assessment and eventual clinical adoption will determine the programme’s commercial significance.